Loading...
Market
Story
FDA Approves Rybrevant for Second-Line EGFR-Mutated Lung Cancer, Reducing Progression Risk by Over 50%
Sep 20, 2024, 05:47 AM
Rybrevant (amivantamab-vmjw), in combination with standard of care chemotherapy, has been approved in the U.S. as the first and only targeted regimen for second-line treatment of EGFR-mutated advanced lung cancer. The approval by the FDA is expected to significantly reduce the risk of disease progression by more than 50%. This marks the third new indication for Johnson & Johnson in 2024. The pharmaceutical giant has set a target of $5 billion in sales for Rybrevant, following this approval for EGFR-positive non-small cell lung cancer (NSCLC) with EGFR ex19del/L858R substitution mutations.
View original story
Similar markets
Less than $2 billion • 25%
$2 billion to $3 billion • 25%
$3 billion to $4 billion • 25%
More than $4 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $1 billion • 25%
$1 billion - $1.5 billion • 25%
$1.5 billion - $2 billion • 25%
More than $2 billion • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
None • 25%
One • 25%
Two • 25%
Three or more • 25%